The North America Genomics In Cancer Care Market would witness market growth of 15.0% CAGR during the forecast period (2024-2031).
The US market dominated the North America Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $13.04 billion by 2031. The Canada market is experiencing a CAGR of 17.5% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 16.5% during (2024 - 2031).
Genomics has revolutionized cancer care by offering insights into the genetic underpinnings of the disease, enabling more precise and personalized approaches to treatment. Genomics plays a crucial role in identifying rare genetic syndromes associated with increased cancer risk.
Additionally, by analyzing whole-genome or exome sequences, clinicians can identify mutations linked to rare inherited cancer syndromes, such as Li-Fraumeni syndrome or Lynch syndrome. Early identification of these syndromes allows for tailored screening and preventive measures for affected individuals and their families.
The growing incidence of cancer in Mexico drives the need for advanced diagnostic tools, including genomic technologies. These tools help in early cancer detection, identifying genetic mutations and biomarkers that can lead to more accurate and timely diagnoses. The increasing cancer burden encourages the expansion of genomic research initiatives in Mexico. Research institutions and universities may intensify their efforts to study cancer genomics, leading to the development of new diagnostic and therapeutic solutions and thus boosting the genomics market.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The US market dominated the North America Genomics In Cancer Care Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $13.04 billion by 2031. The Canada market is experiencing a CAGR of 17.5% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 16.5% during (2024 - 2031).
Genomics has revolutionized cancer care by offering insights into the genetic underpinnings of the disease, enabling more precise and personalized approaches to treatment. Genomics plays a crucial role in identifying rare genetic syndromes associated with increased cancer risk.
Additionally, by analyzing whole-genome or exome sequences, clinicians can identify mutations linked to rare inherited cancer syndromes, such as Li-Fraumeni syndrome or Lynch syndrome. Early identification of these syndromes allows for tailored screening and preventive measures for affected individuals and their families.
The growing incidence of cancer in Mexico drives the need for advanced diagnostic tools, including genomic technologies. These tools help in early cancer detection, identifying genetic mutations and biomarkers that can lead to more accurate and timely diagnoses. The increasing cancer burden encourages the expansion of genomic research initiatives in Mexico. Research institutions and universities may intensify their efforts to study cancer genomics, leading to the development of new diagnostic and therapeutic solutions and thus boosting the genomics market.
Based on Application, the market is segmented into Diagnostics, Personalized Medicine, Drug Discovery & Development, and Research. Based on Product, the market is segmented into Instruments, Consumables, Services. Based on Technology, the market is segmented into PCR, Genome Sequencing, Microarrays, Nuclei Acid Extraction & Purification, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
List of Key Companies Profiled
- Agilent Technologies, Inc.
- F.Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Market Report Segmentation
By Application- Diagnostics
- Personalized Medicine
- Drug Discovery & Development
- Research
- Instruments
- Consumables
- Services
- PCR
- Genome Sequencing
- Microarrays
- Nuclei Acid Extraction & Purification
- Others
- US
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. North America Genomics In Cancer Care Market by Application
Chapter 6. North America Genomics In Cancer Care Market by Product
Chapter 7. North America Genomics In Cancer Care Market by Technology
Chapter 8. North America Genomics In Cancer Care Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation (Beckman Coulter, Inc.)
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- GE HealthCare Technologies, Inc.
- Quest Diagnostics Incorporated
- Revvity, Inc.
- Eurofins Scientific SE
- Hologic, Inc.
Methodology
LOADING...
